Y. Hicheri, G. Cook, C. Cordonnier Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome J. Guinea, M. Torres-Narbona, P.

Prevention of toxoplasmosis in transplant patients

Gut bacterial microbiota and obesity

T. Schneider, J. Halter, D. Heim, J. Passweg, M. Stern, A. Tichelli, M

Anidulafungin for the treatment of invasive candidiasis

Clinical Microbiology and Infection

Migrant health—a cause for concern?

Evolution of extended-spectrum β-lactamases by mutation

Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study N. Lerolle, E. Raffoux, G. Socie, S. Touratier,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil M. Nucci,

J.-P. Van geertruyden Clinical Microbiology and Infection

Y. Hicheri, G. Cook, C. Cordonnier Clinical Microbiology and Infection

Comparison of Photodynamic Therapy versus conventional antifungal therapy for the treatment of denture stomatitis: a randomized clinical trial E.G. Mima,

O. Lortholary, J. -P. Gangneux, K. Sitbon, B. Lebeau, F

R. Cantón Clinical Microbiology and Infection

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

S. Sagedal, A. Hartmann, H. Rollag Clinical Microbiology and Infection

Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease.

Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti- lymphocyte globulin treatment for acute rejection Michael J. Dickenmann,

Clinical Microbiology and Infection

M. Nørgaard, H. Larsson, G. Pedersen, H.C. Schønheyder, H.T. Sørensen

Epidemiology of invasive fungal infections due to Aspergillus spp

Maintenance therapy for cryptococcosis in patients with AIDS after successful primary therapy: oral fluconazole (300 mg daily) versus oral itraconazole.

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients G. Venton,

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998–2007 M.N. Al-Hasan, B.D. Lahr, J.E. Eckel-Passow, L.M.

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive.

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Oral versus intravenous therapy in the treatment of systemic mycosis

Chronic graft-versus-host disease

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome M. Mikulska,

Efficacy of a single intravenous dose of amphotericin B for Candida urinary tract infections: further favorable experience J.F. Fisher, K. Woeltje, A.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Levofloxacin in the treatment of ventilator-associated pneumonia

N.M.A. Blijlevens, J.P. Donnelly, B.E. de Pauw

Metagenomics and probiotics

Long-term mortality following bloodstream infection

The role of antimalarial treatment in the elimination of malaria

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study ( ) A. Xhaard, F. Lanternier, R. Porcher,

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem.

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis J. Gavaldá, T. Martín, P.

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Leishmaniasis in immunosuppressed individuals

The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion

Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? G.N. Pongas, R.E.

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched.

Impact of antibiotic restrictions: the patient's perspective

The future of diagnostic bacteriology

Presentation transcript:

Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri, G. Cook, C. Cordonnier Clinical Microbiology and Infection Volume 18, Pages 1-15 (April 2012) DOI: 10.1111/j.1469-0691.2012.03772.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1. Kaplan–Meier estimates of fungal-free (proven/probable/presumptive) survival (a) and overall survival (b) up to 12 months in a large, randomized, controlled trial comparing voriconazole and fluconazole for primary prophylaxis of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients [34]. Reproduced with permission of the American Society of Hematology, from Wingard et al. [34]; permission conveyed through Copyright Clearance Center, Inc. Clinical Microbiology and Infection 2012 18, 1-15DOI: (10.1111/j.1469-0691.2012.03772.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2. Prophylactic success (composite endpoint combining fungal-free survival and sufficient duration of prophylaxis; adjusted for conditioning regimen and donor relatedness) at day 100 and day 180 in a large, randomized, controlled trial comparing voriconazole and itraconazole for primary prophylaxis of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients [32]. Voriconazole was superior (p <0.01) to itraconazole at both time points. Clinical Microbiology and Infection 2012 18, 1-15DOI: (10.1111/j.1469-0691.2012.03772.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 3. Patient risk stratification and treatment recommendations for primary antifungal prophylaxis in haematology patients as per the ECIL-3 guidelines [56]. AmB, amphotericin B; GvHD, graft-versus-host disease; HCT, haematopoietic stem cell transplant; IV, intravenous. Clinical Microbiology and Infection 2012 18, 1-15DOI: (10.1111/j.1469-0691.2012.03772.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions